Home
Clinical Trials
Phase I Study of BMS-188667 (...

Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

Last Updated: 2011-04-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

1995-08-31

Study Completion Date

1997-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical research study is to determine the safety, pharmacokinetics, immunogenicity in humans, the recovery time required from the biologic effects and the optimal biologic dose range of BMS188667 (CTLA4Ig)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

NCT00287547

Psoriasis Vulgaris

COMPLETED PHASE2

A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris

NCT00277225

Psoriasis Vulgaris

COMPLETED PHASE1

Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

NCT03624127

Psoriasis

COMPLETED PHASE3

Study of BMS-587101 in Patients With Moderate to Severe Psoriasis

NCT00162253

Psoriasis, Moderate to Severe

TERMINATED PHASE2

Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis

NCT02534636

Healthy Subjects

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Abatacept

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women who received adequate counseling and were judged reliabel in their use of contraceptive measures.
* Diagnosis and documentation of stable psoriasis vulgaris of at least 6 months duration.
* Psoriasis vulgaris total body surface area involvement between 10% and 49% (Overall Disease Severity Score \[ODSS\]of 4-7 inclusive).
* Failure of toxicity or inefficacy of at least one standard antipsoriatic therapy including topical treatment, etretinate, phototherapy, or methotrexate.

Exclusion Criteria

* Treatment with: a) Retinoids within 2 years, b) cyclosporin A, systemic corticosteroids, methotrexate, or an investigational agent within 16 weeks, c) any phototherapy or photochemotherapy within 4 weeks d) any topical psoriasis treatment other than emollients within 2 weeks prior to enrollment.
* No clinical response to a prior adequate therapeutic trial of cyclosporin A
* Prolonged exposure to the sun within 4 weeks prior to the first dose.
* Guttate, erythrodermic, or pustular psoriasis.
* Spontaneously improving or rapidly deteriorating psoriasis vulgaris.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers